Progress in clinical researches of immunotherapy for lung cancer targeting PD-1/ PD-L1
10.3872/j.issn.1007-385x.2018.03.001
- VernacularTitle:以PD-1/PD-L1为靶点的肺癌免疫治疗临床研究进展
- Author:
GUO Hanfei
1
;
YU Yu
1
;
CUI Jiuwei
1
Author Information
1. Cancer Center, the First Hospital of Jilin University, Changchun 130021, Jilin, China
- Publication Type:Journal Article
- Keywords:
Lung cancer;
cancer immunotherapy;
immune checkpoint inhibitors;
PD-1/PD-L1
- From:
Chinese Journal of Cancer Biotherapy
2018;25(3):213-220
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] The research on immune checkpoint has made breakthrough progress in recent years. The PD-1/PD-L1 signaling pathway is closely related to the immune escape mechanism, and their inhibitors have also made great success in lung cancer. From Checkmate017, Checkmate-057 to KEYNOTE-010 and OAK studies, PD-1/PD-L1 inhibitors have gradually established their position as standard treatment for the advanced NSCLC patients after chemotherapy failed. PD-1/PD-L1 inhibitors can be combined with other cancer treatment methods, including radiotherapy, chemotherapy, targeted therapy and other immunotherapies, whichhave synergistic effects in the treatment of lung cancer, thus improving the efficacy. Immune checkpoint inhibitors bring changes in the treatment patterns of lung cancer, but also to the traditional efficacy evaluation model,as wellas reaction to the treatment-related adverse. In addition, the development of immune check point inhibitors has effectively promoted the progress of precision medicine.
- Full text:20180301.pdf
